Biotechnology · West Conshohocken, Pennsylvania, United States
$511.97
-0.97% (-$5.03)2026-08-24
Smart-Money SignalNeutral · 44/100— Insiders are net sellers over 90 days (-$2.2M, 13 sales vs 9 buys)
Revenue$364.3M
Net Income-$57.9M
EPS$-5.24
Market Cap$11.8B
Price Performance
Historical data including institutional events
Company Profile
W
William Sibold
CEO & Executive Director
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
